In short
This article discusses a clinical trial investigating the effectiveness and safety of PQ Grass, a treatment for seasonal allergic rhinitis (hay fever) caused by grass pollen in children and adolescents. The study aims to evaluate both short-term and long-term effects of the treatment, as well as its safety profile, in patients aged 4 to 16 years old.
At a glance
- Study Type
- Long-term, double-blind, randomized, placebo-controlled clinical trial
- Medication
- PQ Grass 27600 SU
- Target Population
- Children and adolescents aged 4-16 years with seasonal allergic rhinitis/rhinoconjunctivitis induced by grass pollen
- Study Duration
- Part A: 1 year, Part B: 5 years
- Primary Objectives
- Evaluate efficacy and long-term sustained efficacy of PQ Grass
- Key Measurements
- Combined Symptom and Medication Score (CSMS), Total Combined Score (TCS), grass-specific IgG4 levels, quality of life
- Safety Assessments
- Adverse events, clinical laboratory values, vital signs, spirometry/PEFR (for asthmatic subjects)
What is PQ Grass?
PQ Grass is an investigational medication being studied for the treatment of seasonal allergic rhinitis (hay fever) and rhinoconjunctivitis (inflammation of the nose and eyes) caused by grass pollen in children and adolescents. It is a form of allergen immunotherapy, which means it aims to help your body become less sensitive to grass pollen allergens over time.
Medical Condition Treated
PQ Grass is designed to treat seasonal allergic rhinitis and rhinoconjunctivitis specifically triggered by grass pollen exposure. These conditions cause symptoms like sneezing, runny nose, itchy eyes, and congestion during grass pollen season, typically in spring and early summer.
How PQ Grass Works
PQ Grass works by exposing your immune system to small amounts of grass pollen allergens. Over time, this exposure can help your body build tolerance to these allergens, potentially reducing your allergic reactions when you encounter grass pollen in the environment.
Clinical Trial Overview
A long-term clinical trial is being conducted to investigate the effectiveness and safety of PQ Grass in children and adolescents. The trial is divided into two parts:
- Part A: A one-year study comparing PQ Grass to a placebo (a substance with no active medication)
- Part B: A five-year long-term extension study to evaluate the long-term effects of PQ Grass
The trial is "double-blind," which means neither the participants nor the researchers know who is receiving PQ Grass and who is receiving the placebo during the study.
Eligibility Criteria
To participate in the trial, children and adolescents must meet certain criteria, including:
- Age: 5 to 16 years old
- History of moderate to severe seasonal allergic rhinitis due to grass pollen for at least one year
- Positive skin prick test to grass pollen
- Elevated levels of grass-specific IgE (an antibody associated with allergies) in their blood
There are also several exclusion criteria, such as severe asthma, certain other medical conditions, or recent use of other allergy treatments.
Efficacy Measurements
The main way the researchers will measure how well PQ Grass works is by using a Combined Symptom and Medication Score (CSMS). This score takes into account both the severity of allergy symptoms and the amount of allergy medication needed during grass pollen season. Other measurements include:
- Quality of life assessments
- The number of "well days" and "severe days" during pollen season
- Levels of grass-specific IgG4 (an antibody that may indicate developing tolerance to an allergen) in the blood
Safety Considerations
As with any medical treatment, safety is a crucial aspect of the PQ Grass clinical trial. The researchers will be monitoring:
- Frequency and severity of side effects
- Any serious allergic reactions
- Changes in laboratory test results, vital signs, and lung function tests
It's important to note that PQ Grass is still an investigational treatment, and its full safety profile is not yet known. The clinical trial aims to provide more information about both its effectiveness and potential risks.